Managers / Q2 2025 · view latest →
venBio Partners LLC
CIK 0001776382 · 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94158 · 415-522-0100
Summary
Venbio Partners LLC reported $115M in U.S.-listed holdings across 6 positions for Q2 2025.
The portfolio is heavily concentrated: Pharvaris N V alone accounts for 65.8% of reported value.
Compared with Q1 2025, the fund opened 1 new position and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 65.8% · $75M
- Common Stock · 34.2% · $39M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| LYELLYELL IMMUNOPHARMA INC | NEW | +473.5K | 473.5K | +$4M | $4M |
| ACELYRIN INC | SOLD OUT | −3.81M | 0 | −$9M | $0 |
| LYELL IMMUNOPHARMA INC | SOLD OUT | −7.10M | 0 | −$4M | $0 |
| ALMSALUMIS INC | ADDED | +1.83M | 4.62M | −$3M | $14M |
| ARTVARTIVA BIOTHERAPEUTICS INC | HELD | −50.0K | 1.15M | −$2M | $2M |
| PHARVARIS N V | HELD | +0 | 4.29M | +$8M | $75M |
| ALXOALX ONCOLOGY HLDGS INC | HELD | +0 | 9.70M | −$2M | $4M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | HELD | +0 | 489.2K | −$777,819 | $15M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PHARVARIS N V | COM | 65.78% | $75M | 4.29M |
| 2 | HRMYHARMONY BIOSCIENCES HLDGS INhistory → | COM | 13.47% | $15M | 489.2K |
| 3 | ALMSALUMIS INChistory → | COM | 12.08% | $14M | 4.62M |
| 4 | LYELLYELL IMMUNOPHARMA INChistory → | COM NEW | 3.65% | $4M | 473.5K |
| 5 | ALXOALX ONCOLOGY HLDGS INChistory → | COM | 3.51% | $4M | 9.70M |
| 6 | ARTVARTIVA BIOTHERAPEUTICS INChistory → | COM | 1.51% | $2M | 1.15M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $281M | 6 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $216M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $176M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $115M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 7 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $171M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $194M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $232M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $282M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $667M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $353M | 8 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $276M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $432M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $351M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $451M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $555M | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.0B | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $847M | 10 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $658M | 8 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $38M | 3 | May 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $233M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2019 | $211M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2019 | $225M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2019 | $123M | 4 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.